💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, steadily growing business, priced for perfection.
Torrent Pharmaceuticals is scored on the pharma / healthcare framework. It keeps a healthy 15.4% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.41× reported profit. Free cash flow is worth about -5.4% of its market value.
Over the last 3 years revenue compounded at 13%/yr and profit at 20%/yr. Book value itself has compounded 42%/yr — the hallmark of a genuine compounder. Return on equity is a modest 11.4%. In the latest quarter profit fell 6% versus the prior quarter.
At 74× earnings, the stock sits at the 89th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~29%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 85.92 | — | — |
| P/B | 9.81 | 4.11 | worse |
| EV/EBITDA | 34.26 | 19.15 | worse |
| ROE | 11.42 | — | — |
| ROCE | 11.37 | 6.87 | better |
| ROA | 4.7 | 1.26 | better |
| Quick Ratio | 0.75 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Laurus Labs | 94.7 | 20.8 | 22.1% |
Revenue has grown every year across all 4 financial years shown. 13% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (20% vs 13%) — margin expansion is at work.
Operating margin has expanded from 19% to 21% — the business is keeping more of each rupee earned.
ROE at 12% — a respectable return on shareholder capital. Capital efficiency declining — ROE down 8pp.
EPS has grown every year — each share earns more than the last, consistently. 20% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.4× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Wide quarterly swings (34% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 32% above earlier ones.
Quarterly margins are compressing (19% → 11%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 60.8% — majority control intact. Promoters reduced 7.5pp over 4 quarters — watch whether this is planned divestment or pledge invocations. MF holding up 4.4pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.